科兴生物制药股份有限公司差异化分红事项法律意见书详细解读
近日，科兴生物制药股份有限公司（以下简称“科兴制药”）发布了由北京市嘉源律师事务所出具的关于公司差异化分红事项的法律意见书。该法律意见书对科兴制药实施差异化分红的原因、方案及其合法合规性进行了全面阐述，内容对投资者具有较高的参考价值，并可能对公司股价产生影响。以下为详细要点分析：
一、差异化分红申请原因
- 科兴制药于2024年2月22日和2025年3月17日分别召开董事会会议，审议并通过了以集中竞价交易方式回购公司股份的议案。两次回购分别完成了188万股和151万股的回购。
- 截至申请日，公司回购专用证券账户余额为339.5万股。
- 根据法律法规和公司章程，回购股份不享有表决权、利润分配、公积金转增股本、认购新股和配股等权利。
二、差异化分红方案
- 公司2025年度利润分配将实施差异化分红，具体方案为：以实施权益分派股权登记日登记的总股本扣除回购专用证券账户中股份为基数分配利润。
- 向全体股东每10股派发现金红利2.50元（含税），不进行公积金转增股本，不送红股。
三、分红计算依据及影响
- 参与分配的股本数为197,862,253股（总股本201,257,250股，扣除回购股份）。
- 除权除息参考价格计算：以2026年5月22日收盘价22.86元测算，差异化权益分派对除权除息参考价格影响绝对值为0.0177%，小于1%，影响较小。
- 公司本次分红仅为现金分红，流通股不会发生变化。
四、法律合规性及结论
- 嘉源律师事务所认为，公司此次差异化分红事项符合《公司法》《证券法》《回购股份指引》及公司章程的相关规定，不存在损害公司及全体股东利益的情形。
五、对投资者的重要提示与可能影响
- 回购股份不参与分红，导致实际现金分红基数减少。这意味着分红总金额分配到流通股东，回购股份不会享有利润分配。
- 差异化分红对除权除息价格影响极小（小于1%），但回购减少了分红参与股本，可能提升每股分红水平。
- 公司现金分红方案稳定，未涉及股票分红或转增股本，股东需关注公司现金流及分红政策持续性。
六、潜在影响与投资建议
- 本次差异化分红虽对除权除息价格影响有限，但回购股份后分红基数变化可能对每股分红水平带来积极影响，对价值投资者具有一定吸引力。
- 投资者应重点关注公司未来回购与分红政策的持续性，以及回购股份后分红基数的变化对自身持股收益的具体影响。
免责声明
本文基于公开法律意见书内容撰写，仅供投资者参考，不构成投资建议。投资者应结合自身情况及市场风险，审慎决策。
Sinovac Biotech Differential Dividend Legal Opinion – English Version
Recently, Sinovac Biotech Co., Ltd. (hereinafter “Sinovac”) published a legal opinion from Jia Yuan Law Office regarding its differential dividend matter. The opinion details the reasons, plan, and legal compliance of the company’s differential dividend, offering high reference value for investors and potential impact on share price. Key points analyzed below:
1. Reason for Differential Dividend Application
- On February 22, 2024 and March 17, 2025, Sinovac held board meetings approving proposals to repurchase shares via centralized bidding. Two rounds of repurchase were completed: 1.88 million shares and 1.51 million shares respectively.
- As of the application date, the balance in the dedicated repurchase securities account is 3.39 million shares.
- According to law and company articles, repurchased shares do not enjoy voting rights, profit distribution, capital reserve conversion, new shares subscription, or rights issue.
2. Differential Dividend Plan
- For 2025 profit distribution, Sinovac will implement differential dividends: using total share capital registered on the record date minus repurchased shares as the basis for dividend distribution.
- All shareholders will receive a cash dividend of RMB 2.50 (tax included) per 10 shares. No capital reserve conversion or bonus shares will be issued.
3. Basis and Impact of Dividend Calculation
- Shares participating in distribution: 197,862,253 (total 201,257,250 minus repurchased shares).
- Ex-dividend reference price calculation: using closing price on May 22, 2026 (RMB 22.86), the absolute impact of differential distribution on ex-dividend price is 0.0177%, less than 1%, minimal impact.
- This dividend is cash only; circulating shares remain unchanged.
4. Legal Compliance & Conclusion
- Jia Yuan Law Office concludes that Sinovac’s differential dividend complies with Company Law, Securities Law, Repurchase Guidelines, and company articles, with no harm to the company or shareholders’ interests.
5. Important Notice & Potential Impact for Investors
- Repurchased shares do not participate in dividends, reducing the actual base for cash dividend distribution. This means the total dividend is distributed among circulating shareholders, repurchased shares receive none.
- Differential dividend has minimal (<1%) impact on ex-dividend price, but repurchase reduces distribution base, potentially raising per-share dividend.
- Stable cash dividend policy, no stock dividend or capital reserve conversion. Shareholders should monitor company cash flow and dividend policy continuity.
6. Potential Impact and Investment Advice
- While the impact on ex-dividend price is limited, changes in dividend base due to share repurchase may positively affect per-share dividend, attracting value investors.
- Investors should pay attention to the sustainability of Sinovac’s future repurchase and dividend policies, and the specific impact of changes in dividend base on their shareholding returns.
Disclaimer
This article is based on the contents of the public legal opinion and is for investor reference only. It does not constitute investment advice. Investors should make prudent decisions considering their own circumstances and market risks.
